logo.png
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide
August 05, 2021 06:30 ET | Arch Biopartners
TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
July 14, 2021 07:00 ET | Arch Biopartners
TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
June 10, 2021 07:20 ET | Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19
May 04, 2021 07:00 ET | Arch Biopartners
TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury
April 15, 2021 07:00 ET | Arch Biopartners
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...
logo.png
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
March 30, 2021 07:57 ET | Arch Biopartners
TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
logo.png
Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment
March 24, 2021 08:25 ET | Arch Biopartners
TORONTO, March 24, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the...
logo.png
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
March 16, 2021 08:33 ET | Arch Biopartners
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for...
logo.png
ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp
March 04, 2021 08:32 ET | Arch Biopartners
TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett,...
logo.png
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
February 26, 2021 08:42 ET | Arch Biopartners
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary,...